Male breast cancer in BRCA1 and BRCA2 mutation carriers

Background: BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 mutations. Using the largest available dataset, we determined whether MBCs arising in BRCA1/2 mutation carriers display specific pathologic features and whether these features differ from those of BRCA1/2 female BCs (FBCs). Methods: We characterised the pathologic features of 419 BRCA1/2 MBCs and, using logistic regression analysis, contrasted those with data from 9675 BRCA1/2 FBCs and with population-based data from 6351 MBCs in the Surveillance, Epidemiology, and End Results (SEER) database. Results: Among BRCA2 MBCs, grade significantly decreased with increasing age at diagnosis ( P = 0.005). Compared with BRCA2 FBCs, BRCA2 MBCs were of significantly higher stage ( P for trend = 2 × 10 − 5 ) and higher grade ( P for trend = 0.005) and were more likely to be oestrogen receptor – positive [odds ratio (OR) 10.59; 95 % confidence interval (CI) 5.15 – 21.80] and progesterone receptor – positive (OR 5.04; 95 % CI 3.17 – 8.04). With the exception of grade, similar patterns of associations emerged when we compared BRCA1 MBCs and FBCs. BRCA2 MBCs also presented with higher grade than MBCs from the SEER database ( P for trend = 4 × 10 − 12 ). Conclusions: On the basis of the largest series analysed to date, our results show that BRCA1 / 2 MBCs display distinct pathologic characteristics compared with BRCA1 / 2 FBCs, and we identified a specific BRCA2- associated MBC phenotype characterised by a variable suggesting greater biological aggressiveness (i.e., high histologic grade). These findings could lead to the development of gender-specific risk prediction models and guide clinical strategies appropriate for MBC management. to define ER/PR receptor positivity, which centrally reclassified, owing to the low proportion of records with supporting staining data (Additional file 3). HER2 status was determined using immunohistochemistry (IHC) to detect strong complete membrane staining (with 3+ considered positive) with in situ hybridisation to detect HER2 gene amplification in equivocal cases. Consistency checks were performed to validate receptor data against supplementary scoring information when provided. Central pathology review was not performed.